Developing nanovaccines to treat pancreatic cancer
Anticancer ELNP nanovaccines for curative treatmentof pancreatic cancer
This study is testing a new type of vaccine made from tiny particles to help boost the immune system's fight against pancreatic cancer, and it’s designed for patients with this tough-to-treat disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11040015 on NIH RePORTER |
What this research studies
This research focuses on creating advanced nanovaccines using specialized lipid nanoparticles to treat pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of cancer. The approach aims to enhance the immune response against cancer cells by targeting specific mutations associated with PDAC. By combining these nanovaccines with immune checkpoint inhibitors, the research seeks to improve treatment effectiveness and patient outcomes. Additionally, the study will employ innovative imaging technology to monitor the treatment's impact in real-time, allowing for adjustments to the therapy as needed.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who are seeking innovative treatment options.
Not a fit: Patients with other types of cancer or those who are not diagnosed with pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially increasing survival rates and improving quality of life for patients.
How similar studies have performed: While the use of nanovaccines in cancer treatment is a relatively novel approach, preliminary studies in similar areas have shown promising results in enhancing immune responses against tumors.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Lu, Zheng-Rong — Case Western Reserve University
- Study coordinator: Lu, Zheng-Rong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.